Thursday, 29 December 2016

Global Surgical Procedures Volume Market: Gynecology Segment Surging at Robust Rate, finds TMR

The global surgical procedures volume market is dominated by a few players, although they are facing significant competition from local players in respective regional markets. The availability of advanced wound closure material presents a potential threat for the sutures and staples market. However, surgical handheld instruments face major roadblock only from internal substitutes (electrosurgical devices), having no impact on the overall surgical equipment market.
The global surgical procedures volume market was valued at US$1.3 bn in 2014. Expanding at a healthy CAGR of 5.6% during the forecast period of 2015 to 2023, the valuation is estimated to reach US$2.2 bn by the end of 2024.
Vast Population Base makes Asia Pacific Most Profitable Region
On the basis of procedure, the global surgical procedure volume market has been segmented into cardiovascular, orthopedic, neurosurgery, ophthalmic, gynecology, and other procedures, including urology and dental. The ophthalmic procedure segment held the maximum share in the global market in 2014, accounting for US$42.3 bn that year, primarily due to increasing number of ophthalmic surgeries across the globe and the introduction of advanced surgical technologies. However, the gynecology procedure segment is anticipated to grow at a high CAGR of 6.6% during the forecast period. The prominent factors attributed to this growth include a rise in the prevalence of gynecology diseases, changing lifestyle, and surgical up-gradation. The report finds that in 2014, the volume of surgical procedures was 135,986,269, which is anticipated to reach 222,157,438 by 2023.
Geographically, the report studies the regional markets of North America, Europe, Asia Pacific, Latin America, and the Rest of the World. In 2014, Asia Pacific held the maximum market share, at 40.3%, and the region is expected to remain highly prominent during the forecast period. This demand from Asia Pacific is owing to factors such as massive patient base, increasing incidence of cardiovascular diseases, traumatic injuries, neurological disorders, and the introduction of advanced surgical technologies.
Prevalence of Cardiovascular Diseases Driving Demand
Rising geriatric population directly affects the growth and development of cardiac pacemaker products. This is primarily due to the fact that elderly people are highly susceptible to heart diseases such as sick sinus syndrome and atrioventricular blockage. According to the American Heart Association, cardiovascular disease is the leading cause of death globally. Currently, 17.3 million deaths occur per year. A rise in injuries, technological advancements, and rising incidences of cardiovascular, gynecological, neurological, and urological disorders are also seen as factors boosting market growth
Conversely, the rising cost of healthcare as well as complications and infections related to surgical procedures are the factors that may hinder the growth of the global surgical procedures volume market. The shift towards minimally-invasive surgeries is seen as an opportunity in the market.
The author of the report states, “The future of surgery includes making smaller scars, and giving rise to fewer complications. The focus will be on key technologies such as single-incision laparoscopic surgery (SILS).” The author also identifies the development of robotic surgeries for market players to focus on, which is now widely used in operating rooms to perform highly complex and intricate surgeries, with less pain and recovery time.
The information presented in this review is based on a Transparency Market Research report, titled, “Surgical Procedures Volume Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”
Posted by at No comments:
Labels: , , , , ,

Wednesday, 28 December 2016

Growing Prevalence of Lung Cancer Accelerates Global Non-small Cell Lung Cancer Market

Genentech, a Roche company, dominates the global non-small cell lung cancer (NSCLC) therapeutics market, individually accounting for more than 36% of the market shares in 2014. Transparency Market Research finds that the market is characterized by the presence of both generic and branded companies, and positions Eli Lilly and Company as the second-most prominent player. Rest of the market is fragmented, and highly competitive, with a few formidable players including AstraZeneca plc, Celgene Corporation, Bristol-Myers Squibb, Novartis AG, Pfizer, Inc., Boehringer Ingelheim, and Sun Pharmaceutical Industries Ltd.
Rated as the most dreaded of all types of lung cancer, new NSCLC drugs are readily given approval by regulatory bodies, and research and development is encouraged. This factor is leading to rapid innovation, which will eventually decide the leader of the market in future. The global market for non-small cell lung cancer therapeutics was valued at US$4.9 bn in 2014. Rising at a robust CAGR of 12.10% during the forecast period of 2015 to 2023, the valuation is estimated to reach a US$15.1 bn mark by the end of 2023.
Zykadia Projected for Strongest Growth Rate
The global NSCLC market has been bifurcated on the basis of drugs class, pipeline stage, and geography. By drug class, the market is categorized into angiogenesis inhibitor, epidermal growth factor receptor (EGFR) blocker, kinase inhibitor, folate antimetabolites, microtubule stabilizer, and PD-1/PD-L1 inhibitors. In 2014, the segment of angiogenesis inhibitor dominated the demand, owing to reasons such as high efficacy, targeted therapies, and increasing demand from country-wide markets of the U.S. and Japan. The report rates Zykadia, a sub-segment of kinase inhibitor, for the strongest CAGR during the forecast period, followed by Opdivo, a sub-segment of PD-1/PD-L1 inhibitors.
Geographically, the report studies the regional non-small cell lung cancer therapeutics markets in North America, Europe, Asia Pacific, and Rest of the World. North America dominated the demand in 2014 due to the presence of robust healthcare infrastructure and an efficient government system in the U.S. and Canada. However, Asia Pacific is expected to boost the demand at a stronger CAGR during the forecast period due to vast population, growing awareness about NSCLC, and increased governmental projects related to lung, cancer, and tobacco.
Wide Patient Pool Augmenting Demand
In recent past, the demand for NSCLC therapeutics has surged significantly, and has become the most common type of lung cancer. According to American lung cancer society, about two out of three people diagnosed with lung cancer are 65 years or older. According to the author of the report, “This increasing pool of patients and rising geriatric population across the globe are the primary drivers in the global market for non-small cell lung cancer therapeutics.” Additionally, the author adds that approval of some of the late-stage pipeline products, such as necitumumab and onartuzumab will further fuel the growth rate in positive direction. The report also observes that drugs used in the NSCLC treatment range from regular regimens to targeted therapies, and concurrently are based on simple chemistries to advanced complex protein. As the awareness about the prevalence of lung cancer multiplies, several governments across the globe are offering favorable policies for the players in the market. This factor is also expected to fuel the demand during the forecast period.
The information presented in this review is based on a Transparency Market Research report, titled, “Non-small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”
Posted by at No comments:
Labels: , , ,

Microbiology Culture Market grows with rising demand for antibiotics and the increasing life science research funding

The intense rivalry between Merck Millipore, Thermo Fisher, Sigma-Aldrich, and Becton, Dickinson and Co. characterizes the competitive landscape of the global microbiology culture market, finds a research study by Transparency Market Research (TMR). In 2015, these four players held a share of nearly 53% in the overall market.
With leading participants focusing aggressively towards product innovation and reaching new breakthroughs, the competition within the market is likely to remain high over the next few years. These companies are looking to expand their bases to emerging economies, such as India, Brazil, and China, in order to exploit the untapped opportunities they hold.
According to the research study, the worldwide market for microbiology culture presented an opportunity worth US$4.51 bn in 2014. Progressing at a CAGR of 5.90% during the period from 2015 to 2023, the market is likely to reach US$7.59 bn by the end of the forecast period. Bacterial culture has gained prominence in the global market and is expected to retain it over the period of forecast, expanding at a CAGR of 6.70%.
Significant Rise in Government Funding to Ensure North America’s Lead
The report also analyzes the global market for microbiology culture on its geographical presence. As per the study, Asia Pacific, North America, Europe, the Middle East, Latin America, and the Rest of the World are the main geographical sections of this market. With the significant rise in the government funding to increase research and development activities in microbiology, Europe and North America have emerged as the leading contributors to the global market. Researchers project North America to retain its position with a share of nearly 35% by the end of the forecast period.
On the similar line, Asia Pacific is also anticipated to witness strong growth over the forecast period, thanks to the rise in the disposable income of consumers, advancement in healthcare infrastructure, and the high prevalence of infectious diseases.
Growing usage of Antibiotics in Bacterial and Protozoan Infection Therapeutics to Boost Demand for Microbiology Culture
“The increasing demand for antibiotics is the key factor behind the rising the practice of microbiology culture,” states the author of this study. With the growing usage of antibiotics for the treatment of various bacterial and protozoan infections, the need for its large-scale production has increased substantially as the available quantity of naturally-occurring antibiotics is very less. As a result, microbes are being cultured under controlled conditions to raise their biomass and separate antibiotics from them, which eventually, is leading to a remarkable rise of the global microbiology culture market.
On the flip side, the high costs of culture media and the constant operation of fermentation vessel over a number of weeks may create obstacles to the growth of this market over the next few years. The difficult procedure of alternative nutrient source identification for the progression of various microorganisms in a bid to meet the exact requirements and the urgent need to decrease the cost of large-scale fermentation are also projected to limit microbial culture practices in the coming years, states the research report.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Microbiology Culture Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”
Posted by at No comments:
Labels: , , ,

Increasing Research and Development Activities to Put Global Aptamers Market on Growth Track

The global aptamers market is oligopolistic in nature, led by key players such as Somalogic, Inc., Aptamer Sciences, Inc. and Aptagen, Inc. The top three companies account for 57.8% of the market in 2012. These companies are investing continually in research and development in order to develop novel aptamers for use in various applications such as therapeutics and diagnostics. Companies are striving to gain a better understanding of human biology and diseases, discovery of new drugs, and the development of new diagnostic tests. Companies such as Aptamer Sciences, Inc. provide high quality and cost effective custom aptamers to target various molecules based on specific customer requirements. The company offers more than 200 validated DNA aptamer sequencing for a variety of human target proteins. A new report by Transparency Market Research (TMR) states that antibodies are expected to be a major threat for the aptamers market. As the market for antibodies is well-established, researchers are reluctant to switch to the underdeveloped aptamers market. Thus, the threat of substitute is expected to be high to medium.
According to the report, the global aptamers market is expected to reach US$4,333.0 mn by 2019. On the basis of type, the nucleic acid aptamers market is expected to lead and be worth US$4,333.0 mn by 2019. By application, the market is expected to be led by the therapeutics development segment, which is likely to be worth US$1,452.4 by 2019. This segment is also likely to be expand at the maximum CAGR from 2013 to 2019. On the basis of geography, the market is expected to continue to be led by North America. The North America aptamers market is estimated to reach US$2,029.1 mn by 2019 owing to increasing scientific research and development activities by key players for the development of aptamers.
Rising Support from Various Organizations to Drive Aptamers Market
Aptamers have a great potential and thus, many private organizations in the U.S. and the U.K. are engaged in funding and further development of the aptamer field. This is expected to drive the growth of the market. Aptamers are increasingly being perceived as an attractive solution for research applications owing to the unique production methodology. The production of aptamers do not require animals, thus avoiding animal abuse and death. This eliminates the need for companies to send animal protocol the Institutional Animal Care and Use Committee (IACUC) for aptamer development. Another factor driving the market is the high specificity and selectivity of aptamers, owing to which, the volume required for analysis can be reduced. This helps in increasing the speed of the research analysis, driving their demand.
Lack of Formal Regulatory Guidelines to Pose a Challenge
“There are no formal regulatory guidelines aptamers, which specifically addresses the quality expectations of these drugs.,” says a TMR analyst. The regulatory expectation of aptamer-based drugs is still evolving and the development of regulatory guidelines, which would satisfactorily address quality and safety requirements is challenging. However, aptamer modifications can be made to increase half-life or to enhance therapeutic abilities. In addition to this, chemical structure modification of aptamer can also prove to be beneficial.
This information is based on the findings of a report published by Transparency Market Research titled “Aptamers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.”
Posted by at No comments:
Labels: , , , ,

Diabetes Injection Pens Market: Insulin Pens Show Continued Growth as Users Prefer it Over Pen Needles

According to the research report, the opportunity in the global diabetes injection pens market is expected to be worth US$9.7 bn by the end of 2024 as compared to US$4.9 bn in 2015. Between the forecast years of 2016 and 2024, the global market is projected to rise at a CAGR of 7.9%.
The leading players operating in the global diabetes injection pens market are Novo Nordisk A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports that the competitive landscape in the global market is consolidated due to dominance of a few large players. “Incorporating latest technological innovations to manufacture state-of-art diabetes injection pens will remain the focus of these companies,” states the lead author of this research report.
Insulin Pens Show Continued Growth as Users Prefer it Over Pen Needles
On the basis of product, the global market is segmented into insulin pens and pen needles. Of these, the insulin pens are anticipated to assume the lead in the global market during the forecast period. By the end of 2024, the insulin pens segment is expected to acquire a share of 64.8%. The convenience of using insulin pens as compared to syringes and pumps is expected to drive their demand in the coming years. In terms geography, the global diabetes injection pens market is segmented into North America, Europe, Asia, Latin America, and Rest of the World. Currently, North America holds a dominating share in the global market due to a high degree of awareness about diabetes and its management. Asia Pacific is projected to grow at a steady rate during the forecast period due to a vast pool of patients that are expected to present a score of opportunities.
High Prevalence of Diabetes Creates Ample Opportunities for Diabetes Injection Pens
Poor lifestyle choices and lack of time to exercise are precursors to the life-altering disease known as diabetes. Genetic predisposition and side-effect of other ailments are also to cause diabetes. Statistics presented by the American Diabetes Association state that about 71,000 die each year due to diabetic complications across the U.S. On a similar note, the International Diabetes Federation stated that there were 415 million diabetics across the world in 2015 and the number is estimated to rise by 10% by 2040. These unfortunate figure indicate a high prevalence of diabetes across the world, which is expected to be the primary growth driver for the growth of the global diabetes injection pens market.
The demand for diabetes injection pens is also expected to be fueled by the increasing cases of needle stick injuries. Usage of needles can lead to percutaneous piercing wounds due to incorrect handling, disassembling, or disposing. Owing to this, several healthcare professionals are promoting the usage of injection pens for administering insulin. Design and development of diabetes injection pens that are safe, easy to use, cost-effective, and relatively pain-free are also likely to encourage type 1 diabetics to use them.
Availability of Substitutes Restricts Market Growth
The steady market growth will waver due to the growing number of substitutes in the market. The introduction of a wide range of technologies are offer substitute products are likely to hamper market growth. Furthermore, the possibility of artificial pancreas and disposable insulin patches are also projected to have a negative impact on the global market in the coming years. Poor reimbursement policies for diabetes injection pens is also restraining the growth rate of the global market.
Posted by at No comments:
Labels: , , , ,

Biomedical Refrigerators and Freezers Market: Plasma Freezers to Bring New Opportunities in Market Growth, says TMR

The global biomedical refrigerators and freezers market is fragmented in nature and hence display deep competitive rivalry amongst the already established players. This is the main reason why companies in this market are putting in efforts in order to sustain in the market through constant innovation. The leading companies in the market are Eppendorf AG, Thermo Fisher Scientific, Inc., Helmer Scientific, and Panasonic Healthcare Co., Ltd. These companies are leading the market owing to the extensive product range being introduced by them, robust marketing strategies, and their increasing geographic presence, as per Transparency Market Research (TMR).
The global biomedical refrigerators and freezers market is predicted to touch US$4,003.003 mn in 2022. On the basis of type, the segment of plasma freezers is predicted to lead the market over the forecast horizon. The reason for the dominance of this segment includes the rising count of apheresis procedures and the increasing demand to store fresh frozen plasma. In addition, plasma exchange has come up as the most extensively employed apheresis procedures within the U.S. This will raise the adoption of plasma freezers in research laboratories, hospital settings, and blood banks, thus propelling the growth of the overall market. The global plasma freezers market is predicted to touch US$1,195.515 mn in 2022.
Flourishing Medical Tourism Industry to Bring Exponential Market Growth in Asia Pacific
On the basis of end user, the segment of blood banks led the market in the past owing to the rising availability of expensive freezers and refrigerators within blood banks. On the other hand, the segment of research laboratories is predicted to hold the most lucrative opportunity in the market in forthcoming years owing to growing development in life science research in the developing and developed regions. In addition, the increasing support by government for the production of personalized medicines within developed regions will also fuel the growth of this segment.
Geographically, the North America biomedical refrigerators and freezers market emerged as the top market due to the proliferation of R&D institutes, increasing adoption of cutting-edge technologies, and the advanced healthcare infrastructure of this region. On the other hand, the Asia Pacific biomedical refrigerators and freezers market is poised to rise at the swiftest 6.4% CAGR over the forecast period. This is owing to increasing research and development done by the developing economies and the growing industry for medical tourism in the region of Asia Pacific.
Increasing Demand for Organ Transplant and Biopharmaceuticals to Drive Market Growth
There is an increasing occurrence of organ failures globally. Hence, the global biomedical refrigerators and freezers market is predicted to rise due to the rising demand for organ transplant and biopharmaceuticals. In addition, the growing support provided by government on clinical trials and research activities will positively impact the growth of the biomedical refrigerators and freezers market. Furthermore, technological developments have introduced a paradigm shift from the utilization of conventional equipment to developed technology-based equipment offering efficient energy consumption. Thus, the introduction of numerous technological developments in biomedical refrigerators and freezers are expected to bode well for the growth of the market for biomedical refrigerators and freezers.
On the other hand, this market is highly fragmented in nature and this may result in lower revenues and higher volumes, thus negatively impacting the development of the market. “The increasing usage of refurbished equipment and huge cost of biomedical refrigerators and freezers may also pull back their demand, thus restraining market growth,” says a TMR analyst.
Nonetheless, the growing focus on commercialization and branding of freezers will bring new growth opportunities in the market, states a TMR analyst.
This information is based on the findings of a report published by Transparency Market Research titled, “Biomedical Refrigerators and Freezers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
Posted by at 1 comment:
Labels: , , , , ,

Cardiovascular Monitoring and Diagnostic Devices Market Responds to Impressive Progress in Medicine and Healthcare

Being the leading cause of death and witnessing a high rise in prevalence, the class of ailments that come under the purview of cardiovascular diseases is witnessing increased focus from healthcare, research, and government bodies alike. A large number of companies are venturing into the market with an innovative range of products for diagnosing and treating a variety of cardiovascular diseases. Research and development activities are being granted increasingly more funds and governments bodies are implementing various health schemes aimed at reducing the prevalence and improving awareness about cardiovascular diseases.
Transparency Market Research states that the global cardiovascular monitoring and diagnostic devices market held an opportunity of US$1.8 bn in 2015. The market is expected to expand at a 6.4% CAGR over the period between 2016 and 2024, and rise to a valuation of US$3.1 bn by 2024.
Electrocardiogram (ECG) Systems Lead on Account of Cost Effectiveness and High Efficiency
The product segment of ECG systems presently holds the largest share in the global cardiovascular monitoring and diagnostic devices market. The widespread presence and high preference for ECG systems in developed and developing regions alike are key to the segment’s leading market position. ECG systems are expected to remain the key contributor to the market’s overall revenues over 206 and 2024 as well, expanding at a 6.3% CAGR in the global market.
However, the segment of implantable loop recorders is expected to witness the fastest expansion, a 7.1% CAGR from 2016 to 2024. The segment is projected to benefit from the rising awareness about the use of these devices in diagnosing syncope. As several cases of the disease remain undiagnosed when other conventional diagnostic methods are used, implantable loop recorders are gaining an increased level of adoption across medical diagnostic centers globally. The valuation of the segment is expected to reach US$152.7 mn by 2024.
The segment of Holter monitors also holds immense growth promise owing to the rising prevalence of conditions such as arrhythmia and conduction block. The segment was valued at US$416.1 mn in 2015 and is expected to expand at a high single-digit CAGR from 2016 to 2024.
North America to Continue Taking Largest Share of Pie but Emerging Economies Hold More Promise
North America accounted for the largest share of the overall revenues of the global cardiovascular monitoring and diagnostic devices market in 2015. The region is expected to remain the largest market over the period between 2016 and 2024 as well. Factors such as favorable reimbursement policies, high awareness about available diagnosis and treatment methods among patients and physicians, favorable reimbursement policies, and efficient healthcare infrastructure are factors that will help North America remain at the forefront of the global market. Europe, the second largest contributor to the global cardiovascular monitoring and diagnostic devices market in 2015, will also remain a lucrative owing to large scale healthcare infrastructure development activities and rising prevalence of cardiovascular disease.
However, developing regions such as Latin America and Asia Pacific will present the most promising growth opportunities for the global cardiovascular monitoring and diagnostic devices market over the period between 2016 and 2024. The presence of vast untapped growth prospects, rising healthcare expenditure, and increasing awareness about the efficiency of available techniques and devices in effectively curing several cardiovascular conditions will remain key to the overall growth of the market.
Several research studies also state that the risk of cardiovascular diseases is substantially high in mid- and low-income economies. This substantiates the fact that a large variety of cardiovascular monitoring and diagnostic devices will be consumed in Asia Pacific and Latin America in the next few years. The market for these devices will expand at a 7.5% in Asia Pacific and a 7.3% CAGR in Latin America over the period between 2016 and 2024.
In the highly dynamic global market for cardiovascular monitoring and diagnostic devices market, the top two vendors, GE Healthcare and Philips Healthcare accounted for a more than 55% of the global market in 2015. Other key vendors in the market are Spacelabs Healthcare, St. Jude Medical, Inc., and Siemens Healthcare.
Posted by at No comments:
Labels: , , , , , , , , ,

Incorporation of Technology Overhauls Nurse Call Systems for Real-time Patient Care

Unlike other nursing technologies that have made great strides over the decades, nurse call systems have largely remained the same since their inception in 1860. However, recent technological advancements have resulted in a leap from primitive nurse call system to sophisticated wireless nurse call system. From its simplistic model that involved a bedside button for the patient to summon the nurse, technology is revolutionizing the way patient care functions to match with the times.
With information and communication technology forming an integral part of healthcare services, nurse call systems have taken a new form and shape for improving the quality of communication between patients and nurses. In particular, technology-driven nurse call systems are of immense significance in the event of an emergency, as explained in a new report by Transparency Market Research. On account of the aforementioned factors, the global nurse call systems market is expected to display a CAGR of 13.90% from 2014 to 2020.
Demand for High-quality Patient Care Necessitates Installation of Nurse Call Systems
“An increasing geriatric population across the world is a major factor driving the global nurse call systems market,” says a TMR analyst. This is because this population is susceptible to illnesses and may require hospitalization for dedicated care. The use of nurse call systems for the geriatric population ensures that the patient can raise an alert at the nurse’s station to deliver timely care. This, in turn, allows healthcare organizations to attain seamless communication and streamline nursing activities.
The increasing budget allocation for healthcare of the elderly population is also significantly contributing to the growth of this market. With an increase in the median age of the global population, several countries are focused on providing improved healthcare. Factors such as increasing dependency ratio and the retirement of baby boomers have necessitated the availability of quality healthcare services for aged population.
The increasing need for effective and responsive healthcare communication is another significant factor driving the global nurse call systems market. This is because nursing staff need to be watchful and responsive to provide high quality of healthcare and to ensure patient safety.
“Government regulations in place for the manufacture and distribution of nurse call systems is major impediment to the growth of this market”, says TMR analyst. As per the recent amends by the International Medical Device Regulators Forum (IMDRF), nurse call systems would be included in the category of medical devices. This necessitates nurse call systems to be clinically audited, regulated, and certified.
The IMDRF amend also requires that the software within medical devices need to satisfy medical grade ISO 9000 quality control specifications.
Hospitals Represent Largest End-use Segment
The global nurse call systems market is expected to be worth US$1.57 bn by 2020. Nurse call integrated communication systems is the leading segment of the market on the basis of equipment type; the segment held almost 75% of the overall market in 2013. Nurse call mobile systems equipment type is expected to display significant demand in the foreseeable years. Wired nurse call communication equipment is the largest segment of the market on the basis of communication technology. Hospitals is the largest end-use segment of the nurse call systems market.
The information presented in this review is based on a Transparency Market Research report, titled “Nurse Call Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.”
Posted by at No comments:
Labels: , , , ,

Rising Prevalence of Adverse Drug Reactions Drives Global Pharmacovigilance Market

The global pharmacovigilance market has been responding to a high demand from the healthcare industry, achieving a CAGR of 14.2% between 2014 and 2020. This market was valued at US$2.42 bn in 2012. Owing to its strong growth rate, the market is expected to reach around US$6.1 bn before the end of 2020.Transparency Market Research has released a research report stating these statistics. The report is titled “Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020,” and is expected to impart the most up-to-date knowledge to a user regarding this market.
Pharmacovigilance is a broad term of classification for various aspects of drug safety. It is the science of detecting, monitoring, and curing the negative effects of consuming too many drugs, thereby reducing or negating the side effects and immediate drawbacks of pharmaceutical products.
According to the report, the global pharmacovigilance market is currently being driven by a sharp rise in the number of drug overuse conditions. A growing number of drug toxicity cases are being reported, increasing the demand for pharmacovigilance services.
Additionally, the global pharmacovigilance market is also being fueled by a steadily increasing need from the pharmaceuticals industry to claim negative drug interactions and drug disasters at an earlier stage. This demand, combined with the growing public safety concern over the use of OTC drugs and others has had a visible impact on the global pharmacovigilance market.
The report divides the global pharmacovigilance market on the basis of drug development phase, methods, services, and geography.
On the basis of drug development phases, the global pharmacovigilance market is segmented into Phase I, Phase II, Phase III, and Phase IV/Post Marketing Surveillance. Over 60% of the market was occupied by Phase IV in 2013. Phase IV deal with a systematic and dynamic data collection process, and a marketed drug’s data interpretation. The report, however, expects Phase III to show the fastest growth rate within the given forecast period owing to a greater need for its factors. These include formulation of comparative safety data, study of errors in medication, and drug assessment during development stages.
Spontaneous reporting was the leading method in the global pharmacovigilance market for 2013, and the market analysts believe it will exhibit a steady CAGR for the given forecast period. Its growth rate is attributed to the discovery of drug effects that were previously unknown for existing drugs. This method is also the cheapest one, adding to its preference by medical personnel.
The key players in the global pharmacovigilance market, as described in the report, include Wipro Limited, Novartis International AG, GlaxoSmithKline Plc., Pharmaceutical Product Development, LLC, (PPD), F. Hoffmann-La Roche Ltd., Accenture Plc., Cognizant Technology Solutions, Covance, Inc., Quintiles Transnational Holdings, Inc., and PAREXEL International Corporation.
Posted by at No comments:
Labels: , , , ,

Key factors for Organ Preservation Solutions Market are growing geriatric population & technological developments

The rise in incidences of organ failure in kidney, liver and heart patients across the globe is augmenting the demand for organ transplant procedures.This has further led to rise in the demand for organ preservation solutions that help maintain the organs’ viability from the time of donation to transplantation. Market growth for organ preservation solutions will also be propelled by the rise in the number of elderly people worldwide since, risk of organ failure in people of this age group is higher. Also, the American Society of Nephrology states that an aged patient’s body shows less graft rejection and that has led to increased preference for organ transplants by surgeons for them. According to the U.S. Department of Health and Human Services, in 2011, 60% of the total number of individuals who underwent organ transplantation procedures in the U.S. were beyond 50 years of age. The global market for organ preservation solutions is expected to grow at a CAGR of 16.5% from 2013 to 2019 to reach an estimated value of USD 0.20 billion in 2019.
In case of organ donation surgeries, the process of the perseveration of donated organs starts after the removal of the required organ, such as liver, kidney, heart, or pancreas, from the body of the donor. The organ is placed in a number of layers of sterile containers and an icy slush mixture surrounds these sterile containers. This mixture is known as an organ preservation solution. The goal of this solution is to keep the organs cold but not frozen. This solution aids in maintaining the viability of the organs starting from the time of donation of the organ to the time of transplantation.
As per the report, the increasing technological developments are amongst the key factors fuelling the growth of the market. For instance, Lifeblood Medical, Inc.’s launch of Lifor, also known as blood surrogate, being presently used for research purposes, may effectively be employed for the preservation of veterinary and human organs in the coming years. In addition, the upswing in per capita healthcare expenditure in a number of nations globally will also have a positive impact on the market for organ preservation solutions. Furthermore, the increasing aging population globally will also augment the development of the market. On the other hand, the soaring cost of procedures and the unavailability of organ donors are amongst the chief factors that may impede the growth of the market in the forthcoming years.
On the basis of solution, the report segments the market for organ preservation solutions into Viaspan, Custodiol HTK (Histidine-Tryptophan-Ketoglutarate) Solution, RENOGRAF, HypoThermosol, PERFADEX, Lifor, Human BioSystems (HBS) Solution, siRNA Transplant Solutions, and others. Amongst these, in 2012, Custodiol HTK Solution led the market on the basis of revenue and is poised to expand at the highest growth rate in the forecast horizon. This is owing to its increasing usage in the preservation of various organs such as lungs, liver, pancreas, and kidneys.
By preservation technique, the report segments the market into hypothermic perfusion preservation (HPP), static cold storage (SCS), and others. Amongst these, SCS is leading the market owing to it being a more cost-effective and user-friendly technique for physicians in comparison to HPP. However, HPP is anticipated to experience the highest demand in the forecast period owing to its benefit of organ preservation for longer periods of time. In addition, the decreasing count of organ donors and the rising demand for organs globally will also propel the demand for HPP in the coming years.
Geographically, the market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, in 2012, Europe led the market for organ preservation solutions owing to the rising count of donors within countries such as Spain.
Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Dr. Franz Kohler Chemie GmbH, and XVIVO Perfusion AB, among others are the players dominant in the market, as per this study.
Posted by at No comments:
Labels: , , ,

Increasing Awareness about Chromosome Abnormalities among Women to Augment Demand for Prenatal and Newborn Genetic Testing

The global prenatal and newborn genetic testing market is progressing at a CAGR of 26.9% within a forecast period of 2013 to 2019. The market was valued at US$1.20 bn in 2012. By the end of 2019, this market will be valued at US$8.37 bn, according to a research report released by Transparency Market Research. The report is titled “Prenatal and New-born Genetic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” and provides an estimate for the market’s future using time-tested methods for market analysis. The report is available for sale on the company website, and offers key details on the market through a segmented manner of research.
The growing awareness among consumers regarding chromosome abnormalities in the fetus has presented high-value opportunities to the prenatal and genetic testing service providers. Companies providing prenatal and newborn genetic testing techniques are making continuous efforts to improve the existing technologies and present the market with new breakthrough technologies.
The leading vendors of prenatal and newborn genetic tests are using these developments as a stepping stone for growth. The prenatal and newborn genetic testing market comprises top four companies who held a share of 53% in 2013; the market is expected to show steady growth until 2019. Sequenom Inc. was reported as the company with the largest share followed by Verinata Health, Bio-Rad Laboratories, and Agilent Technologies. The growth of the prenatal and newborn genetic market depends on how vendors capitalize on the potential market in the emerging countries, mainly Asia and Africa.
Advancements in Prenatal and Newborn Genetic Testing Technology to Provide Competitive Advantage to Vendors
All companies in the prenatal and newborn genetic testing industry, primarily use the next generation sequencing technique (NGS) to detect chromosomal anomalies. However, various leading companies use different techniques such as MPSS and target sequencing to detect other abnormalities namely Down Syndrome, Edward Syndrome, and Patau Syndrome. For instance, a Cyprus-based start-up introduced a technique based on the methylated DNA immune precipitation (MeDIP) application. This technique has been reported to be more efficient than the already existing NGS technology. Thus, the rise in new technologies will provide an advantage to vendors of prenatal and newborn genetic tests as they enhance accuracy along with safety of mothers by detecting chromosome abnormalities.
The average maternal age is increasing in developed countries which is leading to the heightened risk of fetal abnormalities among new mothers. The demand for prenatal and newborn genetic tests is expected to rise as a result of the chromosomal anomalies caused due to increased maternal age.
Falling Fertility Rate among Women above 30 Years of Age to Hamper Growth of Prenatal and Newborn Genetic Testing Industry
Recent studies have evidenced that due to harsh environmental factors and changing lifestyles, the ovarian reserve of women is decreasing after the age of 30. The decrease in ovarian reserve also makes women more unfertile after 30, leading to a rise in infertility rate. The increasing infertility rate among women is likely to hinder the growth of the prenatal and newborn genetic market.
On the technological front, diagnostic methods are preferred over screening methods as they are more accurate for the detection of chromosome anomalies. The global market for diagnostic methods is expected to grow at a steady rate and reach US$2633.6 mn by 2019. Apart from this, the entry of new players is expected to increase competition in future, however the untapped market is expected to keep the competitive rivalry at a low level in several regions. North America is reported to the lead the global prenatal and newborn genetic industry followed by Europe in second place. The market for prenatal and newborn genetic testing was worth US$3,854.9 mn in 2015 and is anticipated to reach US$8,377.4 mn by 2019.
Posted by at No comments:
Labels: , , ,

New Trends of Synthetic Biology Market with Worldwide Industry Analysis to 2019

A new Transparency Market Research report states that the global synthetic biology market stood at US$1.8 bn in 2012 and is predicted to reach US$13.4 bn by 2019. It is predicted to expand at a whopping CAGR of 32.60% from 2013 to 2019. The title of the report is “Synthetic Biology Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019.” 
Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. The global synthetic biology market is estimated to be USD 1,769.8 million in 2012 and is expected to reach USD 13,375.5 million by 2019, growing at a CAGR of 32.6% from 2013 to 2019.
Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years.
Synthetic biology market, by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market.
Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period.
Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=421
Europe contributed the largest share of the global synthetic biology market in 2012 and is expected to grow consistently, owing to increasing efforts of government and private organizations towards the development of this field. North America contributed the second largest share of the total market in 2012. Introduction of novel technologies by will help the growth of this market in North America. The Asia-Pacific region is expected to witness the fastest growth due to support of international organizations (e.g. Biotechnology Industry Organization and others) for the growth of synthetic biology in Asia-Pacific.
In terms of key players, the global synthetic biologymarket is highly fragmented with presence of a large number of players that includeBristol Mayer, Gevo, Inc., Life Technologies, DSM, DuPont, Inc., Genomatica, Inc., LS9, Inc.,Amyris, Inc. and others.
Posted by at No comments:
Labels: , , , , ,

Discovery of New Biomarkers to Expand Scope of Immunoprotein Diagnostic Testing, reports

The global immunoprotein diagnostic testing market is led by many global giants. Some of the players operating in the market are Abbott Laboratories, Inc., Abcam PLC, Enzo Life Sciences, Inc., DiaSorin SPA, and Fujirebio Diagnostics, Inc. The distributors in the market, supply products for more than one company. A few substitutes in the market such as molecular diagnostics and microbiology assay are available, but with their own disadvantages. Thus, the threat of substitutes is expected to be low, states a new report by Transparency Market Research (TMR).
High entry barriers such as compliance to regulations and huge capital requirements exist in the immunoprotein diagnostic testing market. However, the threat of new entrants is still expected to be moderate as many new players offer OEM services to the leading players in the market. These small companies can enter the market easily through forward integration.
According to the report, the global immunoprotein diagnostic testing market is expected to be worth US$15.35 bn by 2019. On the basis of assay technology used, the enzyme-based immunoassay segment is expected to lead in the market in the coming years. The market for enzyme-based immunoassay is projected to be worth US$5.34 bn by 2019.
North America to Lead Market owing to Need for Quick Diagnostic Services for Viral Infections and Cancer
By geography, North America is expected to lead in the market and be worth US$6.07 bn by 2019. The market in the region is driven by the demand for quick diagnostic services for viral infections and cancer. The rising trend of preventive healthcare is also creating new opportunities for the market in North America. Additionally, increasing cases of drug abuse and allergies have become major concerns in the U.S., which are further driving the demand for immunoprotein diagnostic testing.
By immunoprotein type, the immunoglobulin diagnostic tests segment is expected to lead in the global market in the coming years. The global market for immunoglobulin diagnostic testing is expected to be worth US$4.7 bn by 2019 owing to a wide scope of application in infectious disease testing, allergy testing, and autoimmune testing.
Rising Prevalence of Diseases to Create Need for Immunoprotein Diagnostic Testing
The rising prevalence of malaria, hepatitis, typhoid, HIV, tuberculosis, and cancer across the globe is driving the global immunoprotein diagnostic testing market. “Many of the diseases have a higher prevalence in underdeveloped economies,” states a TMR analyst. Thus, the demand for low cost, yet effective diagnostic tests is particularly high in underdeveloped nations. A need to diagnose diseases at an earlier stage to avoid severe complications is leading to an increased demand for immunoprotein diagnostic testing kits. Besides this, the market is gaining impetus from technological innovations. Advancements in technology have helped reduce the amount of sample required for tests and also enabled testing for multiple biomarkers in a single assay, reducing the cost per test.
High Cost of Diagnosis Dampening Demand for Immunoprotein Diagnostic Testing
Due to economic crisis, governments of countries such as Germany, France, Spain, Italy, and Hungary have cut down on reimbursement rates, which is increasing the out of pocket expenses of patients. This is limiting the adoption of immunoprotein diagnostic testing. Additionally, the low per capita income of people in many countries have led patients to look for cost effective alternatives for diagnosis. These factors are expected to dampen the demand for immunoprotein diagnostic testing.
Immunochromatography-based Cassette Kits to Emerge as Opportunity for Growth in Market
After the modification of the Clinical Laboratory Improvement Amendments (CLIA) waiver policies, the FDA has approved tests for home use. This has hugely benefitted the home diagnostics market, which is led by immunochromatography-based cassette kits such as pregnancy detection kits, HIV, malaria, and drug abuse testing kits. Additionally, the over-the-counter sale and wide availability of immunochromatography-based cassette kits are expected to drive the market further.
An increased investment in R&D in order to expand the application of the available technologies have led to the introduction of newer products. This has also led to the discovery of new biomarkers such as free light chains, which is acting as an opportunity to expand the scope of market.
This information is based on the findings of a report published by Transparency Market Research titled “Immunoprotein Diagnostic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2019.”
Posted by at No comments:

Virology and Bacteriology Testing Market: Technologies, Markets and Players

Virology and Bacteriology Testing Market: Overview
The study of viruses and bacteria is referred to as virology and bacteriology respectively and includes the identification, classification, and characterization of the various species. The demand for virology and bacteriology testing has increased of late with the growing incidence of various viral and bacterial infections.
The report offers an in-depth assessment on the overall virology and bacteriology testing market, highlighting the leading factors driving and hampering the market. The key opportunities in store and the challenges that lie ahead have also been identified and industry experts have offered their inputs on how to make the most of this information and gain ground in the virology and bacteriology testing market.
The global market for virology and bacteriology testing is studied on the basis of technology, end user, disease, and geography. Based on technology, the market comprises molecular diagnostics, information technology, immunoassays, diagnostic imaging, chromatography, monoclonal antibodies, artificial intelligence, gel microdroplets, differential light scattering, flow cytometry, and liposomes. The key end users of virology and bacteriology testing are clinics, hospitals, diagnostic centers, laboratories, and blood banks. By geography, the market report covers Europe, North America, Latin America, Asia Pacific, and the Middle East and Africa.
Virology and bacteriology testing can be done on a variety of diseases pertaining to the respiratory system, urinary tract, and bloodstream, gastrointestinal and periodontal diseases, sexually transmitted diseases caused by viruses and bacteria, and several other ailments such as connective tissue and joint diseases, central nervous system infections, cardiovascular ailments, and skin diseases.
Virology and Bacteriology Testing Market: Trends and Opportunities
The growth in the global market for virology and bacteriology testing is attributed mainly to the surge in respiratory infections and disorders. According to the World Health Organization, each year at least 3 million people all over the world die from chronic obstructive pulmonary disease (COPD) and at least 235 million people suffer from asthma. This significant patient population, in addition to a growing population of people suffering from tuberculosis, has greatly driven the demand for virology and bacteriology testing. Apart from this, the global market is fueled by rising healthcare expenditure across developed and developing economies, major technological advancements in the field of R&D, and increasing investments by public and private bodies. On the other hand, however, concerns pertaining to reimbursement policies and regulatory scenarios in several developing countries.
It has been observed that most companies have been relying on product development and commercialization in order to gain a larger share in the virology and bacteriology testing market. In addition to this, strategic collaborations also form a key component of many organizations’ growth strategy and recent geographical expansions have enabled these companies to strengthen their hold in the global virology and bacteriology testing market.
Virology and Bacteriology Testing Market: Regional Outlook
Among the key geographical segments covered in the report, North America and Europe are two of the most mature markets for virology and bacteriology testing. Growth in these regional markets has been strong over the years owing to the rapid adoption of advanced diagnostic and testing methods, higher spending on healthcare, presence of favorable government policies, and the presence of advanced clinical laboratories and medical device manufacturing companies. A rising geriatric population and the increasing incidence of various infectious diseases also contribute toward the growth of the virology and bacteriology testing market in North America and Europe.
Asia Pacific is a prominent market for virology and bacteriology testing, powered by emerging economies such as China, Japan, and India. These nations have been generating the maximum revenue owing to expanding R&D facilities in the field of diagnostics, increasing incidence of infectious diseases, and the development of innovative yet affordable testing equipment. Driven by these factors, Asia Pacific will continue to contribute significantly to the global virology and bacteriology testing market.
Companies Mentioned in the Report
Fujirebio Diagnostics Inc., Cepheid, Diasorin, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Scienion AG, Grifols, Qiagen, Eiken Chemical Co Ltd., Sequenom, bioMerieux SA, Siemens AG, Hologic Inc., Diamedix Inc., Leica Biosystems Nussloch GmbH, F. Hoffmann-La RocheLtd., and Abbot are some of the prominent players competing in the global virology and bacteriology testing market.
Posted by at No comments:
Labels: , , ,

Thursday, 22 December 2016

Pulmonary Drugs Market: Launch of Effective Drugs Offers New Ray of Hope to Global Market

This report on pulmonary drugs studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drugs market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.
The global pulmonary drugs market has been exceptionally crucial to the overall healthcare industry over the past few years. According to the research report, the global pulmonary drugs market was worth US$ 48,039.7 mn in 2015 and is likely to reach a valuation of US$ 28,082.1 mn in 2024 as the market will decline at a CAGR of -6.3% during the forecast period of 2016 and 2024. Despite the negative growth rate, the market will find several growth opportunities as the number of chronic respiratory disorders remain on the rise and are fast becoming the cause of death amongst the elderly population.
Combination Drugs Remain Favorite amongst Medical Professionals
On the basis of drug classes the global pulmonary drugs market is segmented into inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), antihistamines, vasodilators, short-acting beta2-agonists (SABA), anticholinergics, combination drugs, and others such as monoclonal antibodies, enzymes, antibiotics, antileukotrienes, etc. Out of these, the combination drugs and inhaled corticosteroids (ICS) held a share of 27.4% and 16.7% respectively in the global market in 2015 in terms of revenue. The demand for combination drugs is estimated to remain high as they are considered to be safer than the others. Furthermore, the introduction of triple combination drugs is also projected to fuel the rise of the global pulmonary drugs market during the forecast period.
Emergence of Middle-income Groups Catapults Demand of Pulmonary Drugs in Asia Pacific
In terms of geography, the global pulmonary drugs market is segmented into Latin America, the Middle East and Africa, Europe, North America, and Asia Pacific. According to analysts, North America held a share of 41.8% in the global market as of 2015. Europe was observed to follow the region’s lead with a significant share of 32.4% in the overall market. The rise of pulmonary drugs market in both these regions is attributable to the well-established health care infrastructure along with an incredible awareness about the treatment options for of pulmonary diseases.
However, analysts anticipate that market in Europe and North America are likely to witness a retarded pace of growth due to patent cliffs in the offing. The U.S. has been making significant contributions to the overall pulmonary drugs market in North America, while Germany remains the steady leader in Europe. The report suggests that Asia Pacific will offer several lucrative opportunities to the global market with the rise of low and middle-income groups and the introduction of several generic pulmonary drugs.
Some of the key players operating in the global pulmonary drugs market are Sunovion Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc, Boehringer Ingelheim GmbH, and Actelion Pharmaceuticals, Inc.
Posted by at No comments:
Labels: , , , ,

Wednesday, 21 December 2016

Arthroscopic Visualization Instruments Market Will Reflect Significant Growth Prospects during 2016-2024

Global Arthroscopic Visualization Instruments Market: Overview
Endoscopy devices have evolved as a promising alternative to minimally invasive surgeries (MIS) and open surgeries. MIS are convenient for patients as well as hospitals, in that they allow quick recovery and reduce hospital stay. They also reduce chances of infections and post surgery complications such as excessive blood loss and infection at the surgery site. Arthroscopy is endoscopy surgery of joints such as knees, shoulder, wrist and others. In an arthroscopy surgery, a surgeon makes a small incision and inserts a rod shaped instrument that consists of a lens and illumination system for clear visualization of internal organs. A camera can also be attached to the arthroscope for better visualization. This method serves the purpose of diagnosis as well as treatment. Arthroscopy surgeries can be advised in cases of osteoarthritis or soft tissue repair such as anterior cruciate ligament (ACL) repair, posterior cruciate ligament (PCL) repair, Achilles tendon repair, labral tear, and others. These injuries are common during sports like football, rugby, tennis, basket ball, cricket where quick movements are common.
Global Arthroscopic Visualization Instruments Market: Segmentation
The field of arthroscopy is continuously evolving with the introduction of advanced technology, which makes it easier for surgeons to reach critical organs, provide better visualization and ergonomic working conditions. Arthroscopy visualization system consists of light source, a camera, and a medical monitor. A light source can be a light emitting diode (LED), xenon or halogen. Currently xenon light sources are widely used as they are lightweight and provide better illumination. To minimize the heat generated by light sources, light is transmitted inside the body through a fiber optic cable. Camera allows better visualization of the surgery process on screen and allows surgeons to save the video files for training and further references. Development in imaging technology has led to the use of high-definition (HD) and three-dimensional (3D) imaging technology to be used in medical field. HD technology provides a wider viewing angle with aspect ratio of 16:9. It also provides better clarity and better color contrast for enhanced visual quality. For HD imaging, all components in a visualization system including camera, monitor, camera control unit and others must be HD compatible. 3D endoscopy provides better depth perception because of its 3 dimensional view. 3D endoscopy also requires all visualization components to be compatible with 3D imaging. In spite of the advantages of 3D viewing, the market for 3D endoscopy is restricted because of the dizziness and eye strain caused to surgeons due to the difference in the view and the natural human eyesight. Nevertheless, although more expensive as compared to earlier 2D endoscopy and with smaller aspect ratio of 4:3, these devices have started capturing the global market.
Global Arthroscopic Visualization Instruments Market: Geographical Dynamics
The market is growing rapidly in Asia-Pacific where countries such as India, China, Japan, Malaysia and others hold great potential. Due to increasing awareness about medical facilities, improving medical services, and increasing preference for minimally invasive surgeries, the arthroscopy market is expected to grow rapidly in this region. Medical tourism is also propelling the market’s growth in Asia-Pacific. The growth will also be leveraged by the rising global aging population, which has increased the incidence of arthritis. Increasing health awareness and sports activities among elderly population have also been observed in the recent past. This has increased the incidence of sports injuries in the age group above 40 years of age. Key players in the market for arthroscopy visualization systems include Olympus, KARL STROZ, Richard Wolf, Stryker, Conmed, Smith & Nephew, and Wright Medical.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Posted by at No comments:
Labels: , , ,
Subscribe to: Posts (Atom)